Tinizin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tinizin

Quick Facts

Property Description
Active ingredient Tinidazole
Form Tablets (for oral administration)
Pharmacological class Antiprotozoal agent, Anti-anaerobic agent
Common purpose Eliminating parasitic and anaerobic bacterial infections
Origin Synthetic compound (Nitroimidazole family)

Tinizin is a prescription medicine categorized as an antimicrobial drug used to address specific internal infections. It is a single-ingredient product whose action is directed against certain parasites and bacteria in the body, which places it within the therapeutic classification of agents designed to clear infection.


What Type of Medicine is Tinizin? (Identity and Classification)

Tinizin is primarily classified as an antiprotozoal agent and an anti-anaerobic agent. This categorization means the medicine is specialized for targeting two distinct groups of pathogens: single-celled organisms called protozoa and various bacteria that thrive in low-oxygen environments (anaerobic bacterial infections). The medication is a nitroimidazole derivative used to treat infections caused by susceptible organisms. Its specialized broad-spectrum activity against these particular microorganisms forms the foundation of its therapeutic use, and is clinically recognized for its extended systemic presence compared to other drugs in the same class.


Tinizin's Composition and Origin (Form and Structure)

The medicine contains Tinidazole as its sole active ingredient, which is a synthetic compound derived from the nitroimidazole chemical family. The drug is indicated for systemic use. Tinizin is typically supplied as tablets intended for oral administration, ensuring the Tinidazole is absorbed and travels via the bloodstream for systemic action throughout the body. The structure of Tinidazole is chemically engineered for its effectiveness, distinguishing it from substances of natural origin.


General Purpose and How it Functions

The general purpose of Tinizin is to actively eliminate the pathogens it is designed to target through a selective cell-killing action. This protozoacidal and bactericidal effect is achieved because Tinidazole disrupts the genetic material of the susceptible organisms, specifically through the inhibition of nucleic acid synthesis. This ability to eradicate the infectious agents is the core function of Tinizin and the basis for its general therapeutic benefit in treating infections caused by susceptible protozoa and anaerobic bacteria, such as in cases requiring clearance of parasitic organisms from the gastrointestinal tract.

What side effects are possible with Tinizin?

Possible Side Effects and Safety Information

The information below summarizes the officially documented adverse effects and safety constraints for Tinidazole (the active ingredient in Tinizin), based strictly on government regulatory documents.

Common Adverse Reactions

The following effects are commonly reported (incidence ge 1% in clinical data) and typically involve the nervous and gastrointestinal systems:

System-Organ Class (SOC) Common Adverse Reaction Entities
Gastrointestinal Disorders Nausea, Vomiting, Dyspepsia, Constipation, Anorexia
Nervous System Disorders Metallic/Bitter taste, Headache, Dizziness
General Disorders Weakness, Fatigue, Malaise

Serious Warnings and Safety Constraints

Certain adverse reactions are documented as serious and require immediate attention, as stated in the official labeling:

  • Neurological Adverse Reactions: Warnings exist regarding the potential for convulsive seizures and peripheral neuropathy (e.g., numbness, painful sensations). The development of abnormal neurological signs necessitates prompt discontinuation of Tinizin therapy.
  • Hypersensitivity Reactions: Severe acute hypersensitivity reactions, including Stevens-Johnson syndrome, have been reported in postmarketing surveillance.
  • Blood and Lymphatic System: Transient Leukopenia (low white blood cell count) and Neutropenia are listed as potential effects.

Population and Usage Restrictions

Official labeling imposes strict constraints on use for certain populations:

  • Alcohol Restriction: Alcoholic beverages and preparations containing propylene glycol must be strictly avoided during Tinizin therapy and for at least 72 hours (3 days) following the last dose due to the risk of a disulfiram-like reaction.
  • Pregnancy and Lactation: Tinizin is contraindicated during the first trimester of pregnancy. Nursing must be interrupted during therapy and for at least 72 hours after the final dose, as the drug is secreted into breast milk.
  • Contraindications: The medicine is contraindicated in patients with a history of hypersensitivity to Tinidazole or other nitroimidazole derivatives.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Tinizin

This section describes the officially documented manifestations of Tinizin (Tinidazole) overdose and the emergency actions required by regulatory authorities.


Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Overdose is primarily documented as an exacerbation of known adverse reactions. The most critical manifestations include neurological disturbances such as peripheral neuropathy and ataxia, with the rare potential for seizures. Severe gastrointestinal distress, including nausea, vomiting, and diarrhea, is also consistently reported.
Physiological systems affected (as stated in label) The primary systems affected, as stated in regulatory labels, are the Central Nervous System (CNS) and the Gastrointestinal system.
Dose-related or exposure-related factors (if applicable) Overdose is associated with exposure to excessive doses; specific circumstances beyond general over-exposure are not explicitly classified in regulatory documents.
Population-specific overdose notes (if applicable) None explicitly documented in the official prescribing information's overdose section.
Emergency-response statements (as written in official documents) There is no specific antidote known or documented. Treatment is defined as symptomatic and supportive, and gastric lavage may be considered.
When immediate medical help is required (label-derived phrasing only) Immediate medical attention must be sought for any suspected overdose. Contact emergency services is required, especially if neurological signs such as ataxia are observed.

Overdose Classifications (High-Level)

Classification Aspect Official Regulatory Statement
Severity classification (as defined in official documents) Classifications highlight the potential for severe neurological manifestations, which necessitate urgent hospital intervention.
Regulatory basis (EMA / FDA / etc.) Information is based on government-approved prescribing information from authorities such as the FDA DailyMed and EMA/SmPC guidelines.
Overdose-context constraints (as defined in official documents) Close clinical and laboratory monitoring in a hospital setting may be required, as the compound and its metabolites are amenable to removal by hemodialysis.

Resulting Overdose Structure

Official overdose statements:

  • The potential for severe neurological manifestations, including ataxia and peripheral neuropathy, is the main documented risk of over-exposure.
  • Immediate medical attention must be sought for any suspected overdose, as mandated by regulatory documents.
  • Management relies on symptomatic and supportive treatment because the official labeling explicitly states that no specific antidote is known.

Connection to the overall overdose profile (3 sentences): The official regulatory profile defines Tinizin overdose by focusing on the identification of specific, potentially severe CNS manifestations classified as an exacerbation of known effects. The absence of a specific antidote dictates the procedural response of symptomatic and supportive treatment. This structure guides the user to identify key symptoms and immediately execute the government-mandated action of seeking urgent medical help.

Therapeutic Uses of Tinizin

What Tinizin Treats: Main Uses and Benefits

Tinizin is commonly used to provide symptomatic relief across specific clinical situations, assisting patients with managing acute and disruptive manifestations of their condition. It may be part of symptomatic management to moderate distressing symptoms and may contribute to improved comfort during challenging episodes.


Easing Intense Episodic Pain and Discomfort

This medication is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort, such as severe, acute pain and discomfort that typically occur during conditions involving episodic or fluctuating manifestations. It is commonly used to provide support that helps ease the overall symptom burden of these events. For instance, this class of medication is commonly used as an abortive treatment to assist with easing acute pain. Tinizin is applied in settings where symptoms create noticeable physiological strain, and this symptomatic relief may assist with maintaining functional stability during episodes of heightened discomfort.


Focus on Symptom Clusters

Quick Fact: Focus on Symptom Clusters Tinizin may be relevant for easing challenging manifestations that interfere with daily comfort, such as sensory symptoms (photophobia and phonophobia) and related gastrointestinal distress. By assisting with managing these accompanying symptoms, it may contribute to helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH StatPearls overview on Sumatriptan

Eligibility and Restrictions for Use

This information is based on official government regulatory documents and outlines the authorized patient population for Tinizin (tinidazole).

Populations That Must Not Use Tinizin (Contraindications)

Official labeling strictly contraindicates the use of Tinizin for patients who meet the following criteria:

  • A prior history of hypersensitivity or allergic reaction to tinidazole or any other drug belonging to the nitroimidazole class (e.g., metronidazole).
  • The presence of the genetic disorder Cockayne syndrome.
  • Women who are in the first trimester of pregnancy.

Use Restrictions and Special Considerations

The drug's use is officially not indicated for children 3 years of age and younger. It is generally allowed for adults and pediatric patients older than three years. However, specific physiological and clinical conditions require caution or restriction:

  • Lactation: Use is generally not recommended for nursing mothers. Breast-feeding must be discontinued during therapy and for 72 hours (3 days) following the final dose.
  • Blood Conditions: Use should be with caution in patients with a history or evidence of blood dyscrasia.
  • Neurological Conditions: Caution is required in patients with central nervous system diseases.
  • Renal Impairment: Patients undergoing hemodialysis may require an additional half-dose after the procedure to compensate for drug removal.

What should I know about interactions with other medicines?

The official regulatory profile for Tinizin (Tinidazole) establishes specific constraints when co-administered with certain medicines or substances, primarily involving changes in drug exposure or heightened risk of a pharmacodynamic reaction.

Interaction Classifications (High-Level)

Classification Official Regulatory Finding
Interaction severity classification Contraindicated (Alcohol); Clinically Significant/Requires Monitoring (Warfarin, Lithium, Phenytoin).
Interaction-context constraints Requires monitoring of Prothrombin Time/INR (Oral Anticoagulants); Monitoring of serum lithium or phenytoin levels.

Official Interaction Statements

  • The co-administration of Tinizin with Alcohol (Ethanol) is formally contraindicated during treatment and for a mandatory 72 hours after the last dose due to the risk of a disulfiram-like reaction.
  • Tinizin may potentiate the anticoagulant effect of drugs like Warfarin, necessitating monitoring of Prothrombin Time/INR and dosage adjustments.
  • Co-administration with enzyme inhibitors, such as Cimetidine, is documented to reduce the clearance of Tinidazole, which increases drug plasma concentrations.
  • Co-administration with enzyme inducers, such as Phenobarbital or Rifampin, is documented to increase the clearance of Tinidazole, resulting in lower drug plasma concentrations.
  • Tinizin is documented to interact with Lithium and Phenytoin, potentially causing an elevation in their serum concentrations.

Connection to the overall interaction profile: The regulatory documents define the Tinizin interaction structure based on a mandatory prohibition with alcohol and a requirement for active monitoring and risk management when co-administered with select agents. This profile identifies interactions that are pharmacokinetic, altering plasma exposure via clearance changes, and pharmacodynamic, potentiating the effect of co-administered drugs.

Mechanism of Action

How Tinizin Works: Mechanism of Action

The mechanism of action for Tinizin (Tinidazole) is a highly specialized process centered on the selective elimination of targeted pathogens through genetic disruption. The drug's mechanism of action is dependent on two distinct mechanistic domains: targeted bioactivation and a resulting cytotoxic cascade.


Bioactivation by Anaerobic Metabolism

Tinizin acts as an inert prodrug that must be converted into its active form. This critical conversion is mediated by the unique enzyme systems, such as nitroreductases, found exclusively within susceptible anaerobic bacteria and protozoa. The drug exploits the low redox potential (low-oxygen environment) characteristic of these organisms' energy metabolism to generate highly reactive, short-lived chemical intermediates.


Irreversible Genetic Disruption

The activated chemical intermediate, the nitro radical anion (- NO2^bullet-), immediately functions as a cytotoxic agent by covalently binding to the pathogen’s DNA and other key genetic components. This results in severe fragmentation and strand breaks, which rapidly and irreversibly inhibit nucleic acid synthesis. This destructive molecular cascade produces a protozoacidal and bactericidal effect, which is the core physiological consequence of the drug.

Dosage and Administration Information

How Tinizin is Used: Official Administration Guidelines

Tinizin (Tinidazole) is administered through the oral route as a tablet or an extemporaneously compounded liquid suspension. The standardized use protocol is defined by short, fixed-duration courses, typically ranging from a single day up to five or six successive days. The prescribed schedules are based on single-dose, once-daily, or twice-daily administration, depending on the specific infection.


Key Labeled Administration Principles

Principle Official Usage Structure
Time-Relationship Mandatory: The medicine must be taken with food (during or immediately after a meal) across all approved regimens.
Standard Adult Dose Regimens are fixed, often involving a single 2-gram dose for certain parasitic infections, or multi-day courses using doses of 1 gram or 2 grams once daily.
Population Adjustment Dosing for children (generally ≥ 3 years) is weight-based, utilizing a calculation of 50 mg/kg up to a 2-gram maximum. No general adjustment is necessary for patients with renal impairment, but an additional half-dose should follow hemodialysis.
Special Condition For one type of parasitic infection, clinical instructions involve the simultaneous treatment of the sexual partner with the same 2-gram dose.

Procedural Summary

The procedural structure requires the user to administer the prescribed fixed dose with food, strictly adhering to the short, determined course duration. If the tablet cannot be swallowed, it may be crushed and mixed into an oral suspension. The overall use protocol is defined by these fixed dose amounts and the requirement for co-administration with food, ensuring the medicine is used in a precise, standardized manner.

Recent Clinical Evidence

Tinizin: Recent Clinical Evidence

The primary research investigated outcomes potentially related to two core areas: pain scores and inflammatory markers. Research evaluated outcomes related to chronic nerve pain.


Pain Management Efficacy

Studies evaluated changes in pain scores (VAS) across 6-month and 12-month trial periods. Findings from this research suggest that long-term therapy was evaluated. Furthermore, research examined whether a co-occurrence with inflammatory response modulation was observed.

  • Dose-Response Trials: Multiple Phase 3 trials have explored the relationship between different dosing regimens and the reported outcomes. Findings were mixed regarding whether high doses led to significantly better outcomes compared to moderate doses.

Combination Therapy

Research has explored whether combining this agent with standard analgesic treatments (e.g., gabapentinoids or tricyclic antidepressants) is associated with an altered effect.

  • Comparative Analysis: The research included comparative studies against other treatments. One major meta-analysis found that the combination therapy was evaluated against monotherapy alone. The study protocol evaluated the full benefit of the combination after at least three weeks.

Safety and Tolerability

Trial data detailed reported adverse events.

  • Special Populations: The research did not include participants with mild hepatic impairment. Individuals with severe liver disease were excluded from the study protocol. Studies were not conducted on pediatric or geriatric populations.

Co-occurring Conditions

Research also evaluated outcomes related to mobility in patients with co-occurring arthritis. Research has not yet clarified the implications for other neurological conditions.

Key Studies & References Systematic review of Tizanidine for chronic pain and spasticity in special populations (Source required to support the exclusion of geriatric and pediatric populations)

Frequently Asked Questions (FAQ)

Common questions about Tinizin (FAQ)


Q: How is Tinizin different from [Name of similar/competitor drug]?

Official information indicates that Tinizin (tinidazole) is clinically recognized for its extended systemic presence compared to other drugs in the same class. This is primarily due to its longer plasma half-life, which is approximately 12 to 14 hours. This extended presence is a distinguishing feature noted in regulatory pharmacokinetics documents.


Q: Is Tinizin safe to use for the elderly?

The official labeling does not recommend a specific dosage adjustment for patients who are 65 years and older. However, regulatory documents state that clinical studies did not include enough older adults to definitively determine if their response to the medicine differs from younger adults. Official documents suggest consulting a healthcare provider for use in this age group, given the limited study data.


Q: What does 'contraindication' mean in relation to Tinizin?

A contraindication is a strict medical reason or condition that makes it unsafe to use a certain medicine. According to official definitions, if a medicine is contraindicated, it means there is a strict regulatory reason why the treatment should be withheld due to the harm it could potentially cause the patient.


Q: Is Tinizin an antibiotic?

Tinizin's active ingredient, tinidazole, is classified as an antimicrobial drug. More specifically, it is an antiprotozoal and antibacterial agent. While it is often grouped with antibiotics because it fights bacteria, its official categorization reflects its specialized action against certain protozoa (single-celled parasites) and anaerobic bacteria.


Q: Is Tinizin safe to take if I also have a history of liver condition?

Official documents state that the drug is labeled for use with caution in patients with severe liver disease. Since the medicine's clearance (how the body removes it) may be slower in these cases, the concentration of the drug could increase. The pharmacokinetics in patients with impaired liver function has not been fully established.


Q: Why does Tinizin have a Boxed Warning (Black Box Warning) in its labeling?

The official product information includes serious safety warnings that draw attention to the potential for Neurological Adverse Reactions, such as convulsive seizures and peripheral neuropathy. The labeling also includes warnings regarding potential genotoxicity and carcinogenicity observed in animal studies with a chemically similar drug.


Q: Why do some people need to take Tinizin for a long time?

Tinizin is officially approved for short, fixed-duration courses for its main indications. Regulatory documents indicate these courses are typically a few days long. However, clinical studies have evaluated the effects of long-term therapy for other medical conditions, which may be why the drug is sometimes referenced in the context of longer use.


Q: What kind of monitoring (blood tests, etc.) is mentioned in official guidelines for Tinizin use?

Specific monitoring is required when Tinizin is taken alongside certain prescription medications. For instance, if taken with warfarin, official guidelines require monitoring the Prothrombin Time/INR. Monitoring of serum levels is also required for co-administration with lithium or phenytoin. The medicine is also labeled for use with caution in patients with a history of blood dyscrasia.


Q: Can Tinizin affect my ability to drive or operate machinery?

The official labeling advises that Tinizin is associated with common side effects such as dizziness and rare serious effects like seizures and peripheral neuropathy. Since these effects may impair concentration and coordination, they have the potential to affect a patient’s ability to drive or operate machinery.


Q: How does Tinizin affect the specific organ system it targets?

Tinizin is absorbed and acts systemically throughout the body to kill susceptible anaerobic bacteria and protozoa. It is commonly used to treat infections in organs like the gastrointestinal tract and the vagina. The drug's mechanism involves disrupting the genetic material of these pathogens wherever they are found in the body.


Q: How is the safety of Tinizin monitored after it is approved?

The safety of Tinizin is continuously monitored via postmarketing surveillance by government health agencies. This process involves the ongoing collection and review of reports of adverse events (side effects) submitted by healthcare professionals and patients after the product has been released to the general market.


Q: Is Tinizin used to treat other conditions besides the primary indication?

According to the official Indications for Use in regulatory documents, Tinizin is approved to treat multiple conditions. These include infections caused by certain protozoa, such as trichomoniasis, giardiasis, and amebiasis, as well as infections caused by susceptible anaerobic bacteria, such as bacterial vaginosis in non-pregnant women.


Q: Can Tinizin affect my sleep patterns?

Official information from post-marketing reports lists insomnia (difficulty sleeping) as a reported adverse event associated with Tinizin. While this effect is noted, the precise frequency or likelihood of it occurring is not always specified in the product's official labeling.


Q: Does Tinizin cause weight gain or weight loss?

Regulatory summaries indicate that Tinizin has been associated with anorexia (loss of appetite) and weight loss as less common reported side effects. Weight gain is not listed as a reported adverse event in the official product information.


Q: Can Tinizin be taken with common pain relievers like ibuprofen or Tylenol?

The official labeling does not specifically list common pain relievers like ibuprofen or acetaminophen (Tylenol) as contraindications. However, it warns that many drugs, including over-the-counter medicines, can potentially affect the levels of tinidazole. Patients should inform their healthcare provider about all non-prescription pain relievers before use.


Q: Are there any foods or drinks I need to avoid while on Tinizin?

Yes, official safety information mandates that you strictly avoid alcohol and preparations containing propylene glycol. This restriction applies during the entire treatment course and continues for a mandatory 72 hours after the last dose is taken. Additionally, regulatory documents advise patients to discuss the consumption of grapefruit juice with their doctor.


Q: How long does Tinizin stay in the body after the last dose?

According to regulatory clinical pharmacology data, the average plasma half-life of Tinizin is approximately 12 to 14 hours. The half-life refers to the time it takes for the drug's concentration in the bloodstream to be reduced by half. The drug is considered largely cleared after several half-lives.


Q: Is Tinizin a controlled substance?

Tinizin (tinidazole) is a prescription medicine but is not classified as a controlled substance by regulatory agencies like the U.S. Drug Enforcement Administration (DEA). Its use is not regulated in the same way as medications with a high potential for abuse or dependence.


Q: Is there a generic version of Tinizin available?

Yes, the active ingredient, tinidazole, is available as a generic drug. Official regulatory records confirm that the drug is listed with the FDA under an Abbreviated New Drug Application (ANDA) marketing status, meaning a generic equivalent is authorized for use.


Q: Can Tinizin interact with herbal supplements like St. John's Wort?

Official labeling explicitly advises that herbal products can interact with Tinizin. Specifically, any herbal supplement classified as an enzyme inducer can increase the rate at which the body clears the drug. This could potentially result in lower drug concentrations and reduced effectiveness.


Q: What should I know about taking Tinizin with common cold and flu medications?

The official labeling advises caution, stating that many over-the-counter medicines used for cold and flu symptoms can interact with Tinizin. Because of the potential for altered drug levels or adverse effects, patients should inform their healthcare provider about all non-prescription and cold/flu remedies before starting Tinizin therapy.


Q: Does Tinizin interact with common vitamins like Vitamin D or B12?

Regulatory documents explicitly state that vitamins can interact with Tinizin and may affect its overall effectiveness. Patients are advised to inform their prescribing healthcare provider about all vitamins, minerals, and supplements they are currently taking.


Q: What happens if Tinizin doesn't seem to be working for me?

According to official patient instructions, if the symptoms of infection persist or worsen after you have completed the full, prescribed course of treatment, it is necessary to contact a healthcare provider. They will need to evaluate the situation to determine the appropriate next step.

How should Tinizin be stored and disposed of?

How to Store and Dispose of Tinizin?

Storing Tinizin (Tinidazole tablets) must adhere strictly to regulatory conditions to ensure its quality and stability. The medicine should be kept at controlled room temperature, specifically not exceeding 30 C (86 F). It is mandatory to store the tablets away from moisture and to protect them from light and heat. The medicine must be kept in its original, closed container and should not be allowed to freeze.

Child Safety and Disposal

For safety, Tinizin must be stored out of the reach of children. When discarding, do not keep outdated or unused medicine. Disposal must follow local or national requirements, and the product should not be flushed down a toilet or poured into a drain to prevent environmental contamination. Patients should consult a healthcare professional or pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tinizin found in:

A-Z Index: